NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV

Attendees will hear from the NCI’s Dr. Genoveffa Franchini about a new HIV vaccine with the potential to prevent HIV infection and treat HIV. The effectiveness of the new vaccine results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is seeking a collaboration partner for the NCI Phase 2 and 3 clinical trials for this vaccine and/or a licensing partner to bring the vaccine to market. Dr. Franchini will also discuss two other NCI technologies that further enhance the vaccine’s effectiveness:

• Improved HIV Vaccines Through Ras Activation
• Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination

Why Attend?

• Assess co-developing and/or licensing this technology
• Interact with the inventor, ask questions and provide feedback
• Learn how to partner with the NCI

Who Should Attend?

• Business development professionals
• Drug development professionals
• Biotech/pharma/academia researchers
• Investors and entrepreneurs

For more information, visit: https://techtransfer.cancer.gov/news#nci-tech-opportunities-webinar-new-hiv-vaccine-treat-and-prevent-hiv